AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7476595
Drug: Pantothenic acid
RxNorm normalized name: Pantothenic Acid
DrugBank: Pantothenic acid (DB01783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantothenic acid replacement therapy, dosage and duration not specified
Trial: 2337215
Drug: Nefopam 20
RxNorm normalized name: nefopam 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 20 mg by intramuscular injection 6 hourly for 24 hours
Trial: 2337215
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg 12-hourly and placebo injections at 6 and 18 hours
Trial: 2337215
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nefopam and diclofenac
Trial: 16837136
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheeting (Cica-Care) applied 24h per day for 6 months
Trial: 16837136
Drug: Control intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control intervention (daily massage for 15 min)
Trial: 16837136
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheeting (Cica-Care)
Trial: 7562017
Drug: One-day antibiotic
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day antibiotic prophylaxis (clindamycin and cefonicid)
Trial: 7562017
Drug: Three-day antibiotic
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day antibiotic prophylaxis (clindamycin and cefonicid)
Trial: 1935632
Drug: CO2‐containing water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2‐containing water (1400 mg CO2/kg H2O) at 34 degrees C for 20 minutes
Trial: 6988950
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg) and tinidazole (2 g)
Trial: 25933795
Drug: Varenicline (VAR)
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline (VAR) 1 mg BID
Trial: 25933795
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX) 25 mg QD
Trial: 25933795
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VAR + NTX
Trial: 19548064
Drug: Intra-articular hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronate (HA) injections
Trial: 11693870
Drug: N,N-diethyl-M-toluamide (DEET)
DrugBank: Diethyltoluamide (DB11282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N,N-diethyl-M-toluamide (DEET) 1.7 g/day
Trial: 3300157
Drug: oxandrolone, 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxandrolone, 0.125 mg/kg/day (Group 2)
Trial: 3300157
Drug: somatrem, 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: somatrem, 0.125 mg/kg 3 times/week (Group 3)
Trial: 3300157
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of somatrem and oxandrolone (Group 4)
Trial: 3300157
Drug: somatrem, 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: somatrem, 0.125 mg/kg 3 times/week and oxandrolone, 0.0625 mg/kg/day (after 12-20 months for Groups 1, 2, and 4)
Trial: 3300157
Drug: somatrem and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: somatrem and combination groups
Trial: 31800354
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 300 mg/day (range 100-600 mg)
Trial: 31800354
Drug: Tetrahydrocannabinol (THC)
RxNorm normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrahydrocannabinol (THC) 10 mg/day (range 5-30 mg)
Trial: 25953805
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 100% fT>MIC
Trial: 25953805
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 50% fT>MIC
Trial: 25953805
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) for piperacillin, baseline to after third TDM
Trial: 22986930
Drug: High-dose retinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose retinol supplement (25,000 IU retinyl palmitate/day) for up to 16 years
Trial: 21839850
Drug: Olodaterol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olodaterol (all doses)
Trial: 21839850
Drug: Olodaterol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olodaterol (40 μg)
Trial: 18068876
Drug: Candidate vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate vaccine (recombinant protein HIV-1 gp160MN/LAI with or without DC-Chol adjuvant) administered by the nasal or vaginal route
Trial: 15199384
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol ester-enriched (PSE) spread (20 g/day)
Trial: 11270916
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/day (increased to 40 mg/day after 2 weeks)
Trial: 11270916
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg/day (increased to 150 mg/day after 2 weeks)
Trial: 11270916
Drug: Combined lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined lithium and antidepressant therapy (both paroxetine and amitriptyline)
Trial: 8119050
Drug: Theophylline concentration
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline concentration of 10 mg/L
Trial: 8119050
Drug: Theophylline concentration
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline concentration of 20 mg/L
Trial: 27461547
Drug: 14mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14mg nicotine patch
Trial: 27461547
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch
Trial: 24892144
Drug: Additional controller
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional controller medications
Trial: 18724650
Drug: Tretinoin 0.04%
RxNorm normalized name: Tretinoin 0.04% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.04% microsphere gel (TMG)
Trial: 7533226
Drug: Moxonidine 0.2-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.2-0.4 mg daily
Trial: 3280266
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg cefuroxime (single intravenous injection)
Trial: 3280266
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg cefuroxime (three doses)
Trial: 3280266
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ceftazidime (single intravenous injection)
Trial: 3280266
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ceftazidime (three doses)
Trial: 27159073
Drug: Emergency Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency Medicine (EM) physicians
Trial: 11322176
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg once daily for 4 days
Trial: 16522657
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg b.i.d. the day before surgery and 600 mg b.i.d. after; administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Trial: 16522657
Drug: Control (placebo)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (placebo) administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Trial: 14653289
Drug: Listerine Original
RxNorm normalized name: Listerine Original Antiseptic Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listerine Original [AP] (alcohol‐containing essential oil/phenolic compound mouthrinse)
Trial: 14653289
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B Sensitive [PF] (phosphoric acid containing fluoride mouthrinse)
Trial: 14653289
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B Tooth & Gum Care [AF] (alcohol‐containing fluoride mouthrinse)
Trial: 14653289
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B Tooth & Gum Care Alcohol Free [OF] (alcohol free fluoride mouthrinse)
Trial: 30924958
Drug: Family‐based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family‐based Treatment for ARFID (FBT‐ARFID)
Trial: 28861202
Drug: Arthroscopically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopically guided suprascapular nerve block and blinded axillary nerve block (10 mL 0.25% ropivacaine)
Trial: 28861202
Drug: Blinded suprascapular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded suprascapular nerve block (10 mL 0.25% ropivacaine)
Trial: 26513517
Drug: ST +
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST + EX (smoking cessation treatment plus exercise intervention)
Trial: 26513517
Drug: ST +
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST + CTRL (smoking cessation treatment plus wellness education control)
Trial: 25155146
Drug: Albiglutide 30
RxNorm normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 30 mg subcutaneous once weekly
Trial: 20444749
Drug: Golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 100 mg plus placebo (group 2)
Trial: 20444749
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg plus methotrexate (group 3)
Trial: 20444749
Drug: Golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 100 mg plus methotrexate (group 4)
Trial: 17383857
Drug: Lamotrigine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (up to 200 mg/day)
Trial: 16274377
Drug: Green Prescription
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Prescription physical activity counseling program
Trial: 12087138
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of lansoprazole daily
Trial: 8551824
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms per h for 5 days) plus endoscopic variceal ligation
Trial: 2182204
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg‐1/hr with alfentanil infusion
Trial: 2182204
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg‐1/hr with alfentanil infusion
Trial: 2182204
Drug: Propofol 4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 4 mg.kg‐1/hr with alfentanil infusion
Trial: 23746674
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation (CRT)
Trial: 19453961
Drug: Gabapentin (600-1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600-1,800 mg per day)
Trial: 17404825
Drug: Intensified LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified LDL-C lowering therapy with ezetimibe
Trial: 17404825
Drug: HDL-C raising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL-C raising therapy with extended-release niacin
Trial: 14697441
Drug: Pentoxifylline (Ptx)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (Ptx) 400 mg, 3 times daily during radiotherapy
Trial: 9404250
Drug: Diltiazem 180
RxNorm normalized name: diltiazem 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 180 mg and trimetazidine 60 mg
Trial: 3500642
Drug: Nabumetone (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (1,000 mg daily)
Trial: 28088674
Drug: Web‐based computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web‐based computer intervention targeting substance use and treatment initiation
Trial: 16782926
Drug: Very accelerated
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very accelerated radiation therapy (62 to 64 Gy in 31 to 32 fractions of 2 Gy over 22 to 23 days)
Trial: 16782926
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation therapy (70 Gy in 7 weeks, 35 fractions of 2 Gy over 49 days)
Trial: 16782926
Drug: Very accelerated
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very accelerated radiation therapy
Trial: 21353749
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (7.7±3.9 mg per day)
Trial: 15333605
Drug: 2 mg/2
RxNorm normalized name: risperidone 2 mg/2 mL ORAL SYRINGE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/2 ml antide (n=30)
Trial: 15333605
Drug: 1 mg/ml
RxNorm normalized name: urea 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/ml antide (n=30)
Trial: 15333605
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml antide (n=31)
Trial: 15333605
Drug: 0.5 mg/0.5
RxNorm normalized name: Dilaudid, 0.5 mg/0.5 mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/0.5 ml antide (n=23)
Trial: 15333605
Drug: 0.25 mg/ml
RxNorm normalized name: thiram 0.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/ml antide (n=30)
Trial: 15333605
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml antide (considered minimal effective dose)
Trial: 9813513
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) infusion during rewarming stage of hypothermic CPB
Trial: 2687645
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 50 mg i.m. every 3 weeks for 12 months + oral calcium supplement (1 g/day)
Trial: 2687645
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + oral calcium supplement (1 g/day)
Trial: 31778478
Drug: Kaolin treatment
RxNorm normalized name: Kaolin
DrugBank: Kaolin (DB01575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaolin treatment (T1): Immature or newly emerged adults of P. solenopsis sprayed with kaolin and fed with cotton leaf discs treated with kaolin suspension.
Trial: 31778478
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water treatment (T2): Immature or newly emerged adults of P. solenopsis sprayed with distilled water and fed with cotton leaf discs treated with distilled water.
Trial: 21293451
Drug: 10-mg CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg CP-945,598
Trial: 21293451
Drug: 20-mg CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg CP-945,598
Trial: 21293451
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lifestyle and CP-945,598
Trial: 15070094
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the stomach
Trial: 15070094
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the proximal small bowel
Trial: 15070094
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the distal small bowel
Trial: 15070094
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the ascending colon
Trial: 9385564
Drug: RO 47‐0203,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 47‐0203, 30 mg/kg orally per day, two single doses
Trial: 8201835
Drug: C2 (rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2 (rifampicin 40 mg/kg and 1200 mg clofazimine once)
Trial: 8201835
Drug: C4 (rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C4 (rifampicin 40 mg/kg, clofazimine 100 mg, DDS 100 mg and ethionamide 500 mg once)
Trial: 2838442
Drug: Neutron boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron boost irradiation (dose levels: 3.6, 4.2, 4.8, 5.2, 5.6, 6.0 Gyn gamma) along with whole brain photon irradiation (1.5 Gy per treatment, 5 days-a-week to a total dose of 45 Gy)
Trial: 28322476
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment with more frequent sessions in a shorter period of time
Trial: 26742305
Drug: Xinfeng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsule (XFC) plus placebo for leflunomide (LEF)
Trial: 21212367
Drug: Iopamidol (370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (370 mg of iodine per milliliter, n = 63)
Trial: 21212367
Drug: Iodixanol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (320 mg of iodine per milliliter, n = 67)
Trial: 18078537
Drug: Risperidone (2‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2‐6 mg/day)
Trial: 18078537
Drug: Haloperidol (2‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2‐40 mg/day)
Trial: 17538084
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with eventual surgery if needed
Trial: 28583757
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (1000 mg at 6-hour intervals)
Trial: 26757748
Drug: Rituximab (RTX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (RTX; anti‐CD20) treatment
Trial: 25178882
Drug: L. salivarius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. salivarius WB21-containing tablets (2.0 × 10(9) colony forming units/day) for 2 weeks
Trial: 25178882
Drug: L. salivarius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. salivarius TI 2711
Trial: 25178882
Drug: Ovalgen® DC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovalgen® DC (antibody against glucosyltransferase from Streptococcus mutans)
Trial: 19622684
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg hydrocortisone (HCORT)
Trial: 17486686
Drug: Fixed valerian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed valerian hops extract combination (Ze 91019)
Trial: 15114701
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day gefitinib
Trial: 15114701
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day gefitinib
Trial: 8151002
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no nicotine patch)
Trial: 21777954
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel with 20 mg esomeprazole
Trial: 21777954
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel with 150 mg ranitidine
Trial: 15249570
Drug: GHRH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (1 mg subcutaneously twice daily)
Trial: 10650325
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g/d orally)